Tuoji Pharmaceutical (Suzhou)

About Tuoji Pharmaceutical (Suzhou)

Phrontline Biopharma, also known as Tuoji Pharmaceutical (Suzhou), is a clinical-stage biotechnology company established in 2022 by a team of industry veterans including Tony (Zhaoyuan) Chen, Siyi Hu, and Yanli Mao. The company specializes in the research and development of next-generation antibody-drug conjugates (ADCs) to treat cancer. Phrontline Biopharma is headquartered in Shanghai and Suzhou, China.

The company's business model centers on its proprietary, end-to-end ADC technology platform which covers antibody discovery, linker-payload engineering, site-specific conjugation, and functional testing. This platform allows for the creation of innovative bispecific antibodies and dual-payload ADCs. These are designed to enhance the precision of payload delivery, overcome drug resistance in tumors, and improve treatment durability compared to single-target approaches. The company's lead asset, TJ101, is a bispecific ADC that targets both EGFR and B7-H3, and is undergoing first-in-human clinical trials in both the United States and China for cancers like non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The pipeline includes nearly ten ADC programs, such as TJ102, which are in preclinical development for various solid tumors.

Phrontline Biopharma generates revenue through strategic collaborations and licensing agreements. A significant partnership with Samsung Bioepis was established in October 2025 to co-develop two next-generation ADC candidates. Another exclusive licensing agreement was made with Sino Biopharmaceutical for the development and commercialization of TJ101 in Mainland China and Hong Kong, which included an upfront payment plus potential future milestones and royalties. The company has successfully raised significant capital to fund its operations. After an Angel Round in March 2022 and a Pre-A round in December 2023, Phrontline closed a $60 million Pre-A+ financing round in November 2025. This round was led by Lapam Investment and included participation from new and existing investors such as Samsung Venture Investment Corporation, Sino Biopharmaceutical Limited, and Decheng Capital. The funds are intended to advance clinical and preclinical programs, expand global operations, and scale manufacturing.